Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Sept. 18 — Sen. Edward J. Markey (D-Mass.) and a bipartisan group of senators Sept. 18 sent a letter to the FDA questioning the agency's approval of the opioid prescription painkiller OxyContin for children as young as 11 years old.
In August, the Food and Drug Administration approved Purdue Pharma LP's OxyContin (oxycodone) for use in pediatric patients 11 to 16 years old for pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The senators said they are concerned about the approval and asked the FDA why it approved the pediatric indication of OxyContin without the benefit of an independent advisory committee review.
Also, the senators said it isn't clear whether the FDA sought any information about the potential for addiction and abuse by children. Children, whose brains aren't yet fully developed, are especially vulnerable to drug dependence and abuse, they said.
“The country is in the midst of an opioid abuse crisis, with more than 2 million Americans aged 12 or older abusing or dependent on opioids,” the letter said. “Opioid overdoses, once almost always due to heroin use, are now increasingly due to abuse of prescription painkillers like OxyContin. We recognize that, in serious cases, children may need appropriately approved and prescribed narcotics. But an increase in the availability of opioids like OxyContin to children—and the potential for abuse—poses a serious U.S. public-health issue.”
• an explanation of why the FDA decided to forgo an advisory committee meeting on the pediatric indication;
• information on any studies the FDA required Purdue Pharma to conduct before approving the pediatric indication;
• an explanation of whether, and if so, how the FDA considered the issues of abuse or addiction by children prescribed OxyContin before the agency approved the indication;
• information on whether the current black box warning for OxyContin is adequate for pediatric use;
• information on the types of medical conditions for which pediatric use of OxyContin is indicated, as well as those for which it isn't indicated;
• a description of how the agency plans to ensure that patients treated with opioids are managed by experienced care teams, and what efforts are under way to educate providers about the pediatric-specific risks associated with the use of opioids;
• a description of what information physicians are required to provide to parents of children receiving OxyContin, including information about potential abuse or dependency; and
• an explanation of how the FDA will be tracking abuse and dependency caused by pediatric use of OxyContin.
Sens. Kelly Ayotte (R-N.H.), Joe Manchin (D-W.Va.), Dianne Feinstein (D-Calif.), Tim Kaine (D-Va.), Angus King (I-Maine), Jeanne Shaheen (D-N.H.) and Dick Durbin (D-Ill.) also signed the letter.
On Sept. 9, Manchin sent a letter to the Senate Health, Education, Labor and Pensions Committee urging it to hold a hearing on the FDA's decision to approve the pediatric use of OxyContin. Manchin also wrote to the FDA in August to express his outrage over the approval decision.
In its approval letter to the manufacturer, the FDA said it will use all available tools to help prevent misuse and abuse of OxyContin. The agency also said it will require Purdue to conduct postmarketing studies aimed at assessing the safe use of the drug in children.
The approval aids prescribers by providing information on how to safely prescribe OxyContin for a certain population of pediatric patients, the FDA said. OxyContin joins Duragesic (fentanyl) as the only extended-release opioid products that are FDA-approved for pediatric use.
To contact the reporter on this story: Bronwyn Mixter in Washington at email@example.com
To contact the editor responsible for this story: Janey Cohen at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)